Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(30 sites)
United States
The University of Arizona Cancer Center, Tucson, Arizona City of Hope, Duarte, California University of Colorado - Aurora Cancer Center, Aurora, Colorado Winship Cancer Center - Emory University, Atlanta, Georgia Ochsner Health, New Orleans, Louisiana Henry Ford Health System, Detroit, Michigan Comprehensive Cancer Center of Nevada, Las Vegas, Nevada Christus St Vincent Regional Medical Center, Santa Fe, New Mexico START New York, Lake Success, New York David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York Icahn School of Medicine at Mount Sinai, New York, New York University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania Prisma Health Cancer Institute, Greenville, South Carolina SCRI Oncology Partners, Nashville, Tennessee Texas Oncology - Central South, Austin, Texas START San Antonio, LLC., San Antonio, Texas Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah START Mountain Region, LLC., West Valley City, Utah Virginia Cancer Specialists, Fairfax, Virginia Virginia Oncology Associates, Norfolk, Virginia Taiwan
Changhua Christian Hospital, Chang-hua E-Da Cancer Hospital, Kaohsiung City Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City Taichung Veterans General Hospital, Taichung China Medical University Hospital, Taichung National Cheng Kung University Hospital, Tainan National Taiwan University Hospital, Taipei Taipei Veterans General Hospital, Taipei Mackay Memorial Hospital, Taipei